For the year ending 2025-12-31, VRCA has $47,131K in assets. $22,388K in debts. $30,147K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 30,147 | |||
| Accounts receivable | 5,260 | |||
| Collaboration revenue, billed and unbilled | 137 | |||
| Deferred r&d services, current portion (note 12) | 1,958 | |||
| Inventory | 2,236 | |||
| Prepaid expenses and other current assets | 2,801 | |||
| Total current assets | 42,539 | |||
| Property and equipment, net | 209 | |||
| Operating lease right-of-use asset | 540 | |||
| Finance lease right-of-use asset | 1,113 | |||
| Deferred r&d services, non-current portion (note 12) | 2,354 | |||
| Other non-current assets | 376 | |||
| Total assets | 47,131 | |||
| Accounts payable | 2,072 | |||
| Accrued expenses and other current liabilities | 12,837 | |||
| Deferred revenue | 782 | |||
| Current portion of long-term debt | 0 | |||
| Operating lease liability | 341 | |||
| Finance lease liability | 405 | |||
| Total current liabilities | 16,437 | |||
| Operating lease liability | 242 | |||
| Finance lease liability | 643 | |||
| Derivative liability | 0 | |||
| R&d funding liability (note 12) | 5,066 | |||
| Long-term debt | 0 | |||
| Total liabilities | 22,388 | |||
| Common stock, 0.0001 par value 200,000,000 authorized 17,189,300 shares issued and 17,178,786 shares outstanding as of december31, 2025 and 9,188,513 shares issued and 9,177,999 shares outstanding as of december31, 2024 | 2 | |||
| Treasury stock, at cost, 10,514 shares as of december 31, 2025 and december 31, 2024 | 0 | |||
| Additional paid-in capital | 349,654 | |||
| Accumulated deficit | -324,913 | |||
| Total stockholders (deficit) equity | 24,743 | |||
| Total liabilities and stockholders (deficit) equity | 47,131 | |||
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)